Incannex Healthcare Beheer

Beheer criteriumcontroles 2/4

De CEO Incannex Healthcare is Joel Latham, benoemd in Jun2018, heeft een ambtstermijn van 5.5 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 3.03M, bestaande uit 27% salaris en 73% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.06% van de aandelen van het bedrijf, ter waarde A$ 59.16K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.4 jaar en 4.3 jaar.

Belangrijke informatie

Joel Latham

Algemeen directeur

AU$3.0m

Totale compensatie

Percentage CEO-salaris	27.0%
Dienstverband CEO	5.5yrs
Eigendom CEO	0.06%
Management gemiddelde ambtstermijn	2.4yrs
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Joel Latham's beloning veranderd ten opzichte van Incannex Healthcare's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2023	AU$3m	AU$820k	-AU$20m
Mar 31 2023	n/a	n/a	-AU$19m
Dec 31 2022	n/a	n/a	-AU$18m
Sep 30 2022	n/a	n/a	-AU$17m
Jun 30 2022	AU$2m	AU$534k	-AU$15m
Mar 31 2022	n/a	n/a	-AU$14m
Dec 31 2021	n/a	n/a	-AU$13m
Sep 30 2021	n/a	n/a	-AU$12m
Jun 30 2021	AU$636k	AU$279k	-AU$11m
Dec 31 2020	n/a	n/a	-AU$6m
Sep 30 2020	n/a	n/a	-AU$5m
Jun 30 2020	AU$390k	AU$227k	-AU$4m
Dec 31 2019	n/a	n/a	-AU$2m
Sep 30 2019	n/a	n/a	-AU$2m
Jun 30 2019	AU$204k	AU$170k	-AU$1m
Mar 31 2019	n/a	n/a	-AU$3m
Dec 31 2018	n/a	n/a	-AU$3m
Sep 30 2018	n/a	n/a	-AU$3m
Jun 30 2018	AU$162k	AU$121k	-AU$3m

Compensatie versus markt: De totale vergoeding ($USD 2.00M ) Joel } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 299.41K ).

Compensatie versus inkomsten: De vergoeding van Joel is gestegen terwijl het bedrijf verliesgevend is.

CEO

Joel Latham (33 yo)

5.5yrs

Tenure

AU$3,033,966

Compensatie

Mr. Joel Bradley Latham has been Chief Executive Officer at Incannex Healthcare Limited (also known as Impression Healthcare Ltd.) since June 29, 2018, Managing Director and Executive Director since July 2...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Joel Latham	MD, CEO & Executive Director	5.5yrs	AU$3.03m	0.060% A$ 59.2k
Madhukar Bhalla	CFO & Company Secretary	2.4yrs	AU$84.00k	geen gegevens
Lekhram Changoer	Chief Technical Officer	1.5yrs	AU$157.50k	geen gegevens
Mark Bleackley	Chief Scientific Officer	no data	geen gegevens	geen gegevens
John Michailidis	Chief Executive Officer of IncannexTM	4.1yrs	geen gegevens	geen gegevens
Rosemarie Walsh	VP of Clinical Operations & Member of the Advisory Board	no data	geen gegevens	geen gegevens
Joseph Swan	Head of Finance	1.3yrs	geen gegevens	geen gegevens

2.4yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IHL wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Joel Latham	MD, CEO & Executive Director	4.4yrs	AU$3.03m	0.060% A$ 59.2k
Mark Bleackley	Chief Scientific Officer	no data	geen gegevens	geen gegevens
Rosemarie Walsh	VP of Clinical Operations & Member of the Advisory Board	no data	geen gegevens	geen gegevens
Terrance O'Brien	Member of the Advisory Board	no data	geen gegevens	geen gegevens
George Anastassov	Non-Executive Director	1.5yrs	AU$175.87k	0.17% A$ 166.8k
Troy Valentine	Independent Non-Executive Chairman	6yrs	AU$1.38m	0.031% A$ 30.8k
Peter Widdows	Independent Non-Executive Director	5.8yrs	AU$316.23k	0.043% A$ 42.6k
Rondhir Jithoo	Member of Medical Advisory Board	4.3yrs	geen gegevens	geen gegevens
Paul Liknaitzky	Member of Medical Advisory Board	3.3yrs	geen gegevens	geen gegevens
Jennifer Walsh	Member of the Advisory Board	no data	geen gegevens	geen gegevens
Robert Clark	Non-Executive Director	1.3yrs	AU$176.09k	0% A$ 0

4.3yrs

Gemiddelde duur

52.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IHL wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Incannex Healthcare Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Incannex Healthcare Inc. Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

Less than half of directors are independent

Incannex Healthcare Limited, Annual General Meeting, Nov 29, 2022

Less than half of directors are independent

Incannex Healthcare Limited Appoints Robert B. Clark to the Board of Directors

Incannex Healthcare Limited Announces Board Changes

Recent updates

Incannex Healthcare Inc. Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

Incannex Healthcare Inc. Receives Approval from the US Food and Drug Administration to Conduct its Investigational New Drug Opening Phase 2 Clinical Trial

Incannex Healthcare Inc. Completes Patient Dosing in 115 Participant Bioavailability/Bioequivalence Clinical Trial for Proprietary Sleep Apnea Drug Candidate IHL-42X

Incannex Healthcare Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Incannex Healthcare Inc. Announces Patient Dosing Commencement in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder

Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Incannex Completes Dosing and Therapy in Phase 2 “Psigad” Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder

Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Incannex Healthcare Ltd. Receives Ethics Board Endorsement for Psychedelic Assisted Therapy At Its First Clinic Based in Melbourne, Australia

Incannex Healthcare Inc Update on Ihl-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea

Incannex Healthcare Inc. SHS to Be Deleted from OTC Equity

Incannex Healthcare Limited Files Form 15

New minor risk - Share price stability

New minor risk - Financial data availability

Psychennex Pty Ltd Commences Preparations of an Investigational New Drug Application to the U.S. Food and Drug Administration

Incannex Healthcare Limited Receives Approval from the US Food and Drug Administration to Conduct Its Investigational New Drug Opening Pivotal IHL-42X Phase 2/3 Clinical Trial in the United States

New minor risk - Market cap size

Incannex Healthcare Limited Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis

Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea

Incannex Healthcare Limited Receives HREC Approval Ph 2 Clinical Trial for IHL675

Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company’S Proprietary Drug for Treatment of Obstructive Sleep Apnoea

Incannex Healthcare Limited Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial

Incannex Healthcare Limited Announces Independent Data Review Commences for PH 2 Trial Psilocybin

Incannex Healthcare Limited Expands Intellectual Property Position over IHL-42X

Incannex Healthcare Limited Announces Development Update for IHL-42X for Obstructive Sleep Apnoea

Less than half of directors are independent

Incannex Healthcare Limited Announces Positive Preliminary Data from Ihl-675A Ph 1 Trial

Incannex Healthcare Limited Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury

Incannex Healthcare Limited, Annual General Meeting, Nov 29, 2022

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.012 loss in FY 2021)

Less than half of directors are independent

Incannex Healthcare Limited Appoints Robert B. Clark to the Board of Directors

Incannex Healthcare Limited (ASX:IHL) completed the acquisition of APIRx Pharmaceuticals USA, LLC from its shareholders.

Incannex Healthcare Limited Engages Curia to Scale-up Manufacture of cGMP IHL-216A

Incannex Healthcare Limited Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A

Incannex Healthcare Limited Announces Board Changes

Less than half of directors are independent

Incannex Healthcare Limited Approves Election of George Anastassov as Director

Incannex Healthcare Limited Announces Positive Results from Phase 2 Clinical Trial Investigating the Effect of IHL-42X for Treatment of Obstructive Sleep Apnoea

Incannex Healthcare Limited Announces Positive Pre-IND Meeting with FDA for IHL-42X for Obstructive Sleep Apnoea

Incannex Healthcare Limited (ASX:IHL) completed the acquisition of APIRx Pharmaceuticals USA, LLC from its shareholders for $93.3 million on May 12, 2022.

Incannex Healthcare Limited Announces IHL-216A Was Observed to Have A Strong Neuroprotective Effect in A Widely Known Model of Sports Concussion

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Incannex Healthcare Limited Completes Dosing Patients in Phase 2 Proof-Of-Concept Trial of IHL-42X for the Treatment of Obstructive Sleep Apnoea

First half 2021 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in 1H 2020)

Incannex Healthcare Limited Files International Patent Application Entitled "Methods for the Treatment of Obstructive Sleep Apnoea" as Part of the IHL-42X Development Program

Company Secretary Glenn Fowles has left the company

Incannex Healthcare Limited Initiates Sixth Research Program Following More Positive in Vivo Results

Incannex Healthcare Limited Partners with Monash Trauma Group At the Department of Neuroscience to Conduct Study in Relation to Neuroprotective Capability of IHL-216A

Incannex Healthcare Limited Initiates Fifth Research Program Following Further Positive in Vivo Results

New 90-day high: AU$0.23

Incannex Healthcare Limited Receives Positive Results from Another in Vivo (Animal) Study

Incannex Healthcare Limited, Annual General Meeting, Jan 25, 2021

Incannex Healthcare Limited Announces Positive Results from IH-216A TBI/Concussion Study

Incannex Healthcare Limited Receives Positive Results from Eurofins

Incannex Healthcare Limited Receives Further Positive Results from Eurofins (Taiwan)

Incannex Healthcare Limited Receives Ethics Approval for Phase 2 OSA Trial

Incannex Healthcare Limited Appoints Paul Liknaitzky to Medical Advisory Board as Scientific Officer

Full year earnings released - AU$0.0058 loss per share

An unknown buyer acquired Gameday International Pty Ltd from Incannex Healthcare Limited (ASX:IHL) for $0.29 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd